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Abstract The aim of this study was to evaluate the long-
term response to rituximab in patients with chronic and
refractory immune thrombocytopenic purpura (ITP). Adults
with ITP fail to respond to conventional therapies in almost
30% of cases, developing a refractory disease. Rituximab
has been successfully used in these patients. We used
rituximab at 375 mg/m
2, IV, weekly for a total of four doses
in 18 adult patients. Complete remission (CR) was
considered if the platelet count was >100×10
9/l, partial
remission (PR) if platelets were >50×10
9/l, minimal
response (MR) if the platelet count was >30×10
9/l and
<50×10
9/l, and no response if platelet count remained
unchanged. Response was classified as sustained (SR)
when it was stable for a minimum of 6 months. Median
age was 43.5 years (range, 17 to 70). Median platelet count
at baseline was 12.5×10
9/l (range, 3.0 to 26.3). CR was
achieved in five patients (28%), PR in five (28%), MR in
four (22%), and two patients were classified as therapeutic
failures (11%). Two additional patients were lost to follow-
up. The median time between rituximab therapy and
response was 14 weeks (range, 4 to 32). SR was achieved
in 12 patients (67%). There were no severe adverse events
during rituximab therapy. During follow-up (median,
26 months; range, 12 to 59), no other immunosuppressive
drugs were used. In conclusion, rituximab therapy is
effective and safe in adult patients with chronic and
refractory ITP. Overall response rate achieved is high, long
term, and with no risk of adverse events.
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Introduction
In immune thrombocytopenic purpura (ITP), platelets are
coated with an IgG autoantibody that prompts its premature
destruction and, as a result, different grades of peripheral
thrombocytopenia and clinical bleeding become evident [5,
23]. Steroids are the first-line treatment for acute ITP. In
case of failure to steroids, splenectomy induces a 70 to 80%
response rate [10]. However, almost 30% of adults with ITP
fail to respond to conventional therapies [steroids, IV
immunoglobulin (IVIg), splenectomy, or immunosuppres-
sive drugs] and, eventually, they develop a chronic
refractory disease [5, 12, 23]. Refractory patients are
defined as those who failed standard-dose steroids and
splenectomy, requiring further treatment due to unsafe
platelet counts (<30×10
9/l) or clinical bleeding. These
patients are unlikely to be cured, although spontaneous
remissions sometimes occur [17]. If a patient becomes
refractory, some alternatives are available such as danazol,
dapsone, azathioprine, high-dose steroids, or chemotherapy
combinations like CHOP regimen. However, these options
are not quite useful because if response is achieved it is but
for a brief period and sustained responses are scarce [23].
Hematopoietic stem cell transplantation has been occasion-
ally used in some cases, but this option represents a high-
risk procedure [14]. At the end, these patients may respond
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e-mail: amajlufc@gmail.compoorly to subsequent therapy, may have significant mor-
bidity from the disease and its treatment (bleeding and
infections secondary to immunosuppressive therapy), and
the mortality rate at 10 years may rise up to 20% [5, 11].
On the other hand, these patients have higher hemorrhagic
risk imposed by trauma or surgery. Therefore, new
treatment strategies for these patients are needed.
Rituximab is an anti-CD20 chimeric murine-human
monoclonal antibody. CD20 is a B-lymphocyte membrane
protein absent on other normal cells. This monoclonal IgG-
kappa antibody is used in non-Hodgkin lymphomas
because it induces apoptosis or direct lysis of B cells [19].
In ITP, B cells are responsible of autoantibody production
and the subsequent platelet opsonization that allows its
destruction. Therefore, if B cell clones are eliminated,
thrombocytopenia could be reverted.
There are some reports informing that rituximab is useful
in refractory ITP showing a high overall response rate, with
complete remission (CR) and partial remission (PR) rates
ranging from 48 to 54% [4, 8, 9, 18, 20–22]. We report
herein our long-term experience with rituximab therapy in
chronic and refractory ITP.
Materials and methods
In a 5-year period, we prospectively administered rituximab
to all patients with chronic and refractory ITP who were
unresponsive to prednisone, azathioprine, vincristine, dana-
zol, and high-dose dexametasone, among other therapies,
including those unsuccessfully splenectomized. Patients
must have a platelet count of <30×10
9/l to be considered
for this therapy.
Rituximab was given in doses of 375 mg/m
2, diluted in
500 ml 5% dextrose–water solution in a 4-h continuous IV
infusion. This regimen was indicated weekly for four doses
after prophylactic application of antipyretic and antihista-
mine premedication administered 30 min before rituximab
infusion (paracetamol, 500 mg, PO; diphenhydramine,
30 mg, PO; and hydrocortisone, 100 mg, IV). Outpatient
follow-up was scheduled monthly for 6 months. Long-term
follow-up was performed every 2 months.
Response was classified as complete (CR) if the platelet
count was >100×10
9/l, partial (PR) if platelet count >50×
10
9/l, minimal response (MR) if platelet count was <50×
10
9/l and >30×10
9/l, and no response (NR) if there was no
change from the baseline platelet count. Response was
sustained (SR) when it was maintained for a minimum of
6 months.
Numerical variables were expressed using the median
and range number. The probability to achieve more than
50×10
9/l and 100×10
9/l platelets and the median time from
response to end of follow-up was calculated using the
Kaplan and Meier method.
Before starting treatment, all patients signed an informed
consent authorization. The procedures done in this protocol
were in accordance with the Helsinki Declaration of 1975.
The protocol was approved by the Ethics Committee of the
participating hospitals.
Results
Eighteen patients were candidates for this therapy, and all
of them were suitable for evaluation because they received
the planned four doses of rituximab. Patient characteristics
and response to rituximab are shown in Table 1. Median
age for the whole group was 43.5 years (range, 17 to 70).
Median platelet count at baseline was 12.5×10
9/l (range,
3.0 to 26.3). Median follow-up was 26 months (range, 12 to
59). Mean number of treatment regimens received before
rituximab was 5.5 (range, 3 to 8). Fifteen patients (83%)
had failed to splenectomy.
CR was achieved in five patients (28%), PR was
obtained in another five (28%), MR was seen in four
(22%) patients, and two patients were considered treatment
failures (11%). Two patients were lost to follow-up (11%).
Ten patients (55%) achieved >50×10
9/l platelets. Median
time from the first rituximab dose to achievement of any
response was 14 weeks (range, 4 to 32). Twelve patients
(67%) showed SR beyond the sixth month of follow-up. As
expected from the results depicted in Table 1, we were
unable to find any correlation between the ITP duration and
the type of response to rituximab. Figure 1 shows the
median platelet counts during follow-up in three different
groups of patients classified according to their pattern of
response (CR, PR, and MR). The median time to achieve
>50×10
9/l platelets was 5 months (95%CI=0.5 to
11.6 months), and the median time to achieve >100×10
9/
l platelets was not reached (Fig. 2). One patient relapsed
22 months after the first course of rituximab. She received
steroids for another 14 months; she did not obtain response,
and a second course of rituximab was given using the
regimen described previously. She achieved a new PR
6 months after stopping therapy. After 22 months of follow-
up, PR still remains in this patient.
Median time of response duration was 54 months (95%
CI=15–93 months) for patients with CR, 18 months (95%
CI=8–28 months) for patients with partial response, and
12 months (95%CI=7–17 months) for those individuals
with minimal response. Difference was statistically signif-
icant between patients in CR vs those achieving PR or MR
(p<0.05). No difference was observed between PR and MR
(Fig. 3).
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fever, chills, and respiratory symptoms were common (8
out of 18 patients, 43%). There were no severe adverse
events during drug administration. Neither hemorrhagic
events nor infections were recorded. Neutropenia, an
occasional long-term side effect of rituximab therapy, was
never recorded in our group of patients (Fig. 4). In fact, the
lower neutrophil count recorded during the study was 1.3×
10
9/l in patient 7 after 6 weeks of treatment with rituximab.
No patient needed additional immunosuppressive therapy
Table 1 Patient characteristics and outcomes
Patient/age/
gender
Evolution
a
(months)
Previous treatments PC at baseline
(×10
9/l)
PC at 12 months
(×10
9/l)
Time to response
(weeks)
Response
type
SR
1/42/F 37 P, S, Az, D, IFN 3.0 146 24 CR Yes
2/43/F 84 P, S, Az, D, IFN, V 5.0 123 24 CR Yes
3/30/F 48 P, S, Az, D, IFN, V 12.5 34. 5 16 MR Yes
4
b/27/F 38 P, S, Az, D, IFN 24.4 78 16 PR
b Yes
b
5/70/M 60 P, Az, D, V 7.8 NR NR NR No
6/43/F 96 P, S, Az, D, IFN, V 10.1 37.7 8 MR Yes
7/53/F 96 P, S, Az, D, IFN, V 12.5 54 12 PR Yes
8/36/F 264 P, S, Az, D, IFN, V,
OE, IVIg
5.0 30.6 4 MR Yes
9/17/F 38 P, S, Az, D, IFN, V,
OE
6.5 129 4 CR Yes
10/57/F 26 P, Az, D 8.3 64 8 PR Yes
11/36/F 25 P, S, Az, D, IFN, V 7.0 49 20 MR No
12/63/F 120 P, Az, D, V 26.3 NR NR NR No
13/53/F 348 P, De, D, S, Az 22.0 112 8 CR Yes
14/22/F 266 P, S, D, IFN, IVIg 12.6 67 12 PR No
15/56/F 137 P, D, S, Az 18.4 223 4 CR Yes
16/35/F 38 P, D, Az, S 23.2 11.4 0 NR No
17/52/F 41 P, D, S 16.5 51.9 4 PR Yes
18/24/F 60 O, D, S 24.0 NR NR NR No
PC Platelet count, P prednisone, S splenectomy, Az azathioprine, D danazol, IFN interferon alpha 2b, V vincristine, De dexamethasone, OE
opsonized erythrocytes
aTime from ITP diagnosis to rituximab therapy
bA second course of rituximab was given
Fig. 1 Platelet count achieved
after first dose of rituximab
(time 0 first dose of rituximab).
Diamonds, CR; ovals, PR;
triangles,M R
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no other illnesses have been recorded in this group of
patients.
Discussion
Because almost 30% of individuals with ITP do not
respond to the first- and second-line therapies, they live
with low platelet counts, a situation that carries a high risk
of hemorrhage and, eventually, a short life expectancy. It
has been largely demonstrated that ITP with persistent low
platelet counts carries a grave prognosis [6, 13]. Efforts to
increase the platelet count to at least 30×10
9/l include IVIg,
anti-D immunoglobulin, cyclophosphamide, polychemo-
therapy such as the CHOP regimen, thrombopoietin,
interleukin-11, dapsone, alpha interferon, plasma exchange,
and bone marrow transplantation [23]. Using these thera-
pies, the response rate is low and the patient is exposed to
unnecessary risks [10]. When the first ITP patient success-
fully treated with rituximab was informed, it drew the
attention of physicians because this regimen offered high
response rate and low toxicity. In subsequent reports,
researchers have found similar results.
The aim of this study was to evaluate the response rate
achieved in 18 patients with chronic and refractory ITP
after rituximab treatment as well as the evolution of these
patients to learn about the possible long-term side effects
associated with the use of this drug, information that is
Fig. 4 Mean (squares), maximum (diamonds), and minimum (tri-
angles) neutrophil counts through the follow-up of patients receiving
rituximab for chronic and refractory ITP
Fig. 3 Median duration of response for patients who achieved
complete remission (CR; 54 months, 95%CI=15–93 months), partial
remission (PR; 18 months, 95%CI=8–28 months), or minor response
(MR; 12 months, 95%CI=7–17 months)
Fig. 2 Time required to obtain platelet counts >50×10
9/l (a)o r
>100×10
9/l (b) after first dose of rituximab in adult patients with
chronic and refractory ITP
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favorable responses (67%) and at least a stable clinical
evolution in two additional patients (11%), for a global
response rate of 78%. Based on the characteristics of the
evolution of our group of patients, we may emphasize some
points of interest: (1) Response rate obtained was quite
satisfactory considering the history of chronicity and
refractoriness of the patients; (2) the monoclonal antibody
was well tolerated and caused only mild allergic reactions
that could be easily managed with antihistaminics and
paracetamol; (3) most of the patients achieve SR; and (4)
increase of platelet count was not always immediate
(median time to response=14 weeks), a fact that slightly
disagrees with previous reports that found shorter time to
response (3 to 8 weeks; Table 2)[ 4, 8, 20]. In fact, in a
recent systematic review about the efficacy of rituximab in
adult patients with ITP, it was found that median time to
response was 5.5 weeks (ranges 2 to 18 weeks) [2]. We do
not have an explanation for this discrepancy. After a careful
analysis, we did not find significant differences between the
results obtained in the systematic review and our results in
terms of the variables that may affect the time to response
to rituximab, namely, age, sex, previous use of cortico-
steroids, number of treatments before rituximab, rituximab
dose and schedule, period between diagnosis and rituximab
administration, duration of ITP before rituximab, and
pretreatment platelet counts. Although splenectomy may
not be a significant predictor of response to rituximab as
previously suggested [2, 4, 8], it should be noted that 83%
of the patients included in our report had had splenectomy
as compared with 50.5% of the patients in the systematic
review. Therefore, history of splenectomy seems to be the
only factor related to a different time to response to
rituximab in our series.
Of course, we have no data about all possible variables
influencing the pattern of response to rituximab. For
example, we do not show information about B-cell counts
and platelet autoantibodies before and after rituximab
therapy, two variables that may influence the response as
observed in other trials. The expected therapeutic effect of
rituximab is a reduction in specific platelet-associated
autoantibodies and the consequent increase in platelet
counts. Although rituximab has not been always associated
with a reduced load of platelet autoantibodies and most of
the publications reporting this effect are small series of
cases [1], the high overall response rate obtained in our
study allows us to believe that rituximab effectively
decreased the B-cell counts as well as the levels of platelet
autoantibodies.
Three patterns of response to rituximab have been
proposed: early (before the fourth dose of rituximab),
intermediate (7 to 11 weeks after rituximab), and delayed
(>13 weeks after rituximab) [8]. In our study, the
probability to achieve a platelet count >50×10
9/l occurred
at a median of 5 months, so we speculate that the complete
inhibition of antibody formation and restoration of platelet
counts with rituximab may occur after at least 5 months
(95%CI=0.5 to 11.6 months) from the first dose of the
antibody (Fig. 2). However, some patients may achieve a
quite delayed response (as long as 1 year after therapy), a
situation in which it is important to wait a reasonable time
period before another treatment is planned.
A previous report informed the results obtained in
patients treated with the same regimen as we used [4].
After a median follow-up of 47 weeks, the authors observed
a lower overall response rate of 44% (CR=18%, PR=15%,
MR=10%); most of the responses were sustained. They
observed two response patterns: (1) an early-response group
in which responses appeared within the first 2 weeks after
the first dose of rituximab; (2) a late-response group
characterized by an increase in platelets several weeks after
rituximab. Finally, after a median follow-up of 72.5 weeks,
the response rate was 54% with a majority of SR [8]. In a
prospective trial performed in pediatric patients with
chronic ITP, treatment with rituximab produced an increase
of >50×10
9/l platelets in 11 of 36 children (31%) [3].
Median time to response was 1 week (range, 1 to 7 weeks);
however, a 6% incidence of serum sickness was observed.
More recently, one of the largest experiences in ITP patients
treated with rituximab was published [15]. An increase of
>50×10
9/l platelets was observed in 55% of the patients
(CR=46%, SR=35%). The only predictive factor for SR
was to achieve CR. Patients who were treated more
intensively (more than three different treatments) and those
with a longer ITP duration (>10 years from diagnosis) had
the worse response. In this study, non-splenectomized
patients had a higher early response rate than those
splenectomized. Although some of these results are similar
Table 2 Patterns of response
in patients with chronic and
refractory ITP (from [1, 6, 18])
OR Overall response, CR
complete response, PR partial
response
Reference Number of patients OR (%) CR (%) PR (%) Median time to response (weeks)
Mayo clinic 12 50 42 8 ?
USA–Italy 57 53 31 22 8
Denmark 35 33 18 15 2–8
Peru 22 68 40 27 ?
Mexico 18 56 28 28 14
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results seen in our study are partially explained by differ-
ences in the inclusion and response criteria used, in the
evolution time of the disease, and in the number and type of
treatments given before rituximab.
As early relapses may be seen in ITP patients treated
with rituximab and because re-treatment with this mono-
clonal antibody offers good results [16], this drug has been
used as a long-term maintenance treatment. Based on long-
lasting remissions achieved using one or two doses of
rituximab [7] and the results of late responders, we feel that
a single dose of 375 mg/m
2 every 6 months could be an
alternative for this purpose.
On the other hand, because of the mechanism of action
of rituximab and its interference with the immune system,
we searched for possible long-term complications associat-
ed with its use, namely, neoplasias, chronic infections, or
autoimmune diseases. Immune status is a major concern in
patients treated with rituximab being the induction of low
CD20+ counts and hypogammaglobulinemia (specifically
low levels of immunoglobulin M), two previously reported
secondary effects. Although we do not have data about
these two immunological variables, the lack of severe
infectious diseases during the long-term follow-up of our
patients allows us to speculate that no severe immune
abnormalities were developed in our series. As we
previously stated, during the follow-up period, no associ-
ated illnesses or pathological phenomena were observed. To
our knowledge, this seems to be the first report about the
lack of long-term complications associated with rituximab.
In conclusion, rituximab is a long-term, safe, and
effective alternative treatment of chronic and refractory
ITP patients. Prospective randomized clinical trials are
needed to elucidate the efficacy of the drug in comparison
to splenectomy in early stages of the disease
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